153 related articles for article (PubMed ID: 37758559)
21. Revisiting Intermittent Therapy in Metastatic Prostate Cancer: Can Less Be More in the "New World Order"?
Shevach J; Sydes MR; Hussain M
Eur Urol Focus; 2019 Mar; 5(2):125-133. PubMed ID: 30803926
[TBL] [Abstract][Full Text] [Related]
22. Variation in chromogranin A serum levels during intermittent versus continuous androgen deprivation therapy for prostate adenocarcinoma.
Sciarra A; Monti S; Gentile V; Mariotti G; Cardi A; Voria G; Lucera R; Di Silverio F
Prostate; 2003 May; 55(3):168-79. PubMed ID: 12692782
[TBL] [Abstract][Full Text] [Related]
23. Intermittent androgen deprivation therapy may prolong the duration of androgen dependence of well-differentiated prostate cancer.
Kaneko Y; Maekawa S; Arakaki R; Okada Y; Terada N; Nishimura K
Hinyokika Kiyo; 2006 Apr; 52(4):259-64. PubMed ID: 16686352
[TBL] [Abstract][Full Text] [Related]
24. Is time to castration resistant prostate cancer a potential intermediate end-point for time to metastasis among men initiating androgen deprivation therapy for non-metastatic prostate cancer with rapid PSA doubling time (<9 months)?
Klaassen Z; Howard L; Wallis CJD; Janes JL; De Hoedt A; Aronson WJ; Polascik TJ; Amling CJ; Kane CJ; Cooperberg MR; Terris MK; Wu Y; Freedland SJ
Prostate Cancer Prostatic Dis; 2023 Mar; 26(1):151-155. PubMed ID: 36050455
[TBL] [Abstract][Full Text] [Related]
25. Does race predict the development of metastases in men who receive androgen-deprivation therapy for a biochemical recurrence after radical prostatectomy?
Vidal AC; Howard LE; De Hoedt A; Kane CJ; Terris MK; Aronson WJ; Cooperberg MR; Amling CL; Lechpammer S; Flanders SC; Freedland SJ
Cancer; 2019 Feb; 125(3):434-441. PubMed ID: 30427535
[TBL] [Abstract][Full Text] [Related]
26. [Hormonal therapy for prostate cancer: methods and prognosis].
Huang BX; Su HC; Cao WL; Sun FK
Zhonghua Nan Ke Xue; 2013 Sep; 19(9):815-9. PubMed ID: 24386861
[TBL] [Abstract][Full Text] [Related]
27. [Risk factors for early castration-resistant prostate cancer after androgen deprivation therapy for bone-metastatic prostate cancer].
Huang FM; Li XH; Liang Y
Zhonghua Nan Ke Xue; 2018 Aug; 24(8):690-694. PubMed ID: 30173426
[TBL] [Abstract][Full Text] [Related]
28. Effectiveness of Adding Docetaxel to Androgen Deprivation Therapy for Metastatic Hormone-Sensitive Prostate Cancer in Korean Real-World Practice.
Park K; Kim JY; Park I; Shin SH; Lee HJ; Lee JL
Yonsei Med J; 2023 Feb; 64(2):86-93. PubMed ID: 36719015
[TBL] [Abstract][Full Text] [Related]
29. Obesity is associated with castration-resistant disease and metastasis in men treated with androgen deprivation therapy after radical prostatectomy: results from the SEARCH database.
Keto CJ; Aronson WJ; Terris MK; Presti JC; Kane CJ; Amling CL; Freedland SJ
BJU Int; 2012 Aug; 110(4):492-8. PubMed ID: 22094083
[TBL] [Abstract][Full Text] [Related]
30. [Androgen deprivation therapy in advanced prostate cancer. Multicenter study.].
Valencia-Guadalajara VJ; Martínez-Cayuelas L; Sarrió-Sanz P; Sánchez-Caballero L; Polo-Hernández R; Chillón-Sempere FS; Galán-Llopis JA; Garcés-Valverde M; Tenza-Tenza JA; Costa-Martínez A; García Serrado-Paumard D; Escudero-Fontana E; Tello-Royloa C; Verdú-Verdú LP; Bravo-López DF; Pérez Seoane-Ballester H; Pacheco-Bru JJ; Ortiz-Gorraiz MÁ
Arch Esp Urol; 2020 Jul; 73(6):499-508. PubMed ID: 32633245
[TBL] [Abstract][Full Text] [Related]
31. Potential benefits of intermittent androgen suppression therapy in the treatment of prostate cancer: a systematic review of the literature.
Abrahamsson PA
Eur Urol; 2010 Jan; 57(1):49-59. PubMed ID: 19683858
[TBL] [Abstract][Full Text] [Related]
32. [Availability of Local Therapy to Castration-Resistant Prostate Cancer for M0 Patients with Initial Prostate Specific Antigen 100 ng/ml or Higher].
Kuromoto A; Tanaka T; Koyama J; Goto T; Kimura S; Katsumata Y; Myoen S; Ozawa M; Morozumi K; Sato M; Hoshi S; Numahata K; Arai Y
Hinyokika Kiyo; 2017 Dec; 63(12):515-520. PubMed ID: 29370662
[TBL] [Abstract][Full Text] [Related]
33. Factors predicting progression to castrate-resistant prostate cancer in patients with advanced prostate cancer receiving long-term androgen-deprivation therapy.
de la Taille A; Martínez-Piñeiro L; Cabri P; Houchard A; Schalken J;
BJU Int; 2017 Jan; 119(1):74-81. PubMed ID: 26919403
[TBL] [Abstract][Full Text] [Related]
34. Intermittent hormone therapy in nonmetastatic prostate cancer.
Opfermann KJ; Lai Z; Essenmacher L; Bolton S; Ager J; Forman JD
Clin Genitourin Cancer; 2006 Sep; 5(2):138-43. PubMed ID: 17026802
[TBL] [Abstract][Full Text] [Related]
35. Pre-existing Castration-resistant Prostate Cancer-like Cells in Primary Prostate Cancer Promote Resistance to Hormonal Therapy.
Cheng Q; Butler W; Zhou Y; Zhang H; Tang L; Perkinson K; Chen X; Jiang XS; McCall SJ; Inman BA; Huang J
Eur Urol; 2022 May; 81(5):446-455. PubMed ID: 35058087
[TBL] [Abstract][Full Text] [Related]
36. Differences in time to disease progression do not predict for cancer-specific survival in patients receiving immediate or deferred androgen-deprivation therapy for prostate cancer: final results of EORTC randomized trial 30891 with 12 years of follow-up.
Studer UE; Whelan P; Wimpissinger F; Casselman J; de Reijke TM; Knönagel H; Loidl W; Isorna S; Sundaram SK; Collette L;
Eur Urol; 2014 Nov; 66(5):829-38. PubMed ID: 23932338
[TBL] [Abstract][Full Text] [Related]
37. Mass spectrometry redefines optimal testosterone thresholds in prostate cancer patients undergoing androgen deprivation therapy.
Beck J; Rouleau M; Lemire F; Neveu B; Déry M; Thériault B; Dubois G; Guérette D; Pouliot F
Prostate; 2023 May; 83(7):670-677. PubMed ID: 36851864
[TBL] [Abstract][Full Text] [Related]
38. Population-based Assessment of Intermittent Androgen Deprivation Therapy Utilization for Relapsed, Nonmetastatic, Hormone-sensitive Adenocarcinoma of the Prostate.
Janzen BW; Ong A; Penner M; Koul R; Dubey A; Ahmed S; Bashir B; Chowdhury A; Dawe DE; Nayak J; Kim JO
Am J Clin Oncol; 2020 Dec; 43(12):865-871. PubMed ID: 32976179
[TBL] [Abstract][Full Text] [Related]
39. Prediction of Time to Castration-Resistant Prostate Cancer Using Bone Scan Index in Men with Metastatic Hormone-Sensitive Prostate Cancer.
Miyoshi Y; Yoneyama S; Kawahara T; Hattori Y; Teranishi JI; Ohta JI; Takebayashi S; Yokomizo Y; Hayashi N; Uemura H
Urol Int; 2017; 99(4):400-405. PubMed ID: 28609769
[TBL] [Abstract][Full Text] [Related]
40. Strategy for PSA progression in patients undergoing salvage radiation for biochemical recurrence after radical prostatectomy.
Saito T; Matsumoto K; Kosaka T; Yasumizu Y; Tanaka N; Takeda T; Morita S; Mizuno R; Asanuma H; Oya M
Int J Clin Oncol; 2023 May; 28(5):707-715. PubMed ID: 36929093
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]